TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31606939
Drug: Continuous NB‐UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous NB‐UVB therapy (Side A)
Study: 31606939
Drug: Interrupted NB‐UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted NB‐UVB therapy (Side B)
Study: 31606939
Drug: Continuous NB‐UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous NB‐UVB treatment (Group 2)
Study: 31606939
Drug: Interrupted NB‐UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted NB‐UVB treatment (Group 3)
Study: 27189212
Drug: Bosentan dosing
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan dosing regimen
Study: 22170367
Drug: caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine (3 mg caffeine/kg)
Study: 17696221
Drug: Current and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current and emerging therapies for HRS
Study: 15827365
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (1.25 mg/24-h)
Study: 10540564
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (dry powder with ISF system) 12 mcg twice daily
Study: 10540564
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mg qid)
Study: 8535647
Drug: Combination studies
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination studies and meta-analyses
Study: 7032291
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg every 6 hours)
Study: 7032291
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg every 6 hours)
Study: 28741044
Drug: Asenapine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (5-10 mg/day)
Study: 28741044
Drug: Olanzapine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-10 mg/day)
Study: 22260818
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1600 mg daily
Study: 22260818
Drug: Anti‐rheumatic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐rheumatic therapy alone
Study: 16330884
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone substitution in GH‐deficient patients
Study: 12000778
Drug: DOTS without
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS without direct observation (self-administered)
Study: 9798134
Drug: 7-day estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day estrogen matrix patch (Climara) at 0.5 mg/day
Study: 9798134
Drug: 7-day estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day estrogen matrix patch (Climara) at 0.1 mg/day
Study: 9798134
Drug: 0.625-mg/day oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625-mg/day oral conjugated equine estrogen
Study: 9798134
Drug: 7-day estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day estrogen patch
Study: 6996120
Drug: sotalol 160
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol 160 - 800 mg
Study: 6996120
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 - 500 mg
Study: 17644623
Drug: Hypertension and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension and diabetes medications (in women)
Study: 10979113
Drug: Niacin (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (3000 mg/d)
Study: 6322709
Drug: Cimetidine, 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1,200 mg/day
Study: 6322709
Drug: Cimetidine, 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 2,400 mg/day
Study: 6322709
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg/day
Study: 30875247
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg oral, thrice weekly for 48 weeks)
Study: 28025189
Drug: Cardiopoietic cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopoietic cells in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients)
Study: 26292180
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony (TGP) 1.8 g/day combined with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Study: 26292180
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TGP) with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Study: 21535424
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for first-episode psychosis participants (n = 25)
Study: 21535424
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for stable psychosis patients (n = 15)
Study: 17123219
Drug: Specific aftercare
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific aftercare measures after inpatient therapy
Study: 8387177
Drug: Neoadjuvant MVP
Normalized name: MVP-S
DrugBank: Maveropepimut-S (DB17339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant MVP (mitomycin, vindesine/vinblastine, higher-dose cisplatin)
Study: 3500381
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tobramycin (5.1 mg/kg/day for 9 days)
Study: 3500381
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily tobramycin (5.1 mg/kg/day for 9 days)
Study: 29095725
Drug: Guided Internet-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-Based Cognitive Behavior Therapy (iCBT) for tinnitus over 8 weeks
Study: 29095725
Drug: Weekly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly monitoring (control group)
Study: 12641503
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1000 IU) and calcium citrate (800 mg) daily (group A)
Study: 12641503
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (25 mg b.d., group B)
Study: 12641503
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (1 mg every 3 months, group C)
Study: 30780196
Drug: Vortioxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine combined with cognitive behaviour intervention therapy
Study: 27419388
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity aerobic exercise program (3 times weekly for 4 months on a bicycle ergometer at 60-70% heart rate reserve)
Study: 22682213
Drug: Treatment received
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment received during the trial
Study: 19733016
Drug: Postoperative continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative continuous accelerated irradiation (p‐CAIR) therapy
Study: 19733016
Drug: Postoperative conventional
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative conventional fractionation (p‐CF) therapy
Study: 11756862
Drug: Avonex treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex treatment
Study: 9370894
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg elemental zinc per day)
Study: 4043200
Drug: Piretanide treatment
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide treatment in patients with ascites
Study: 4043200
Drug: Piretanide treatment
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide treatment after resolution of ascites
Study: 4043200
Drug: Piretanide treatment
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide treatment in patients with diuretic resistant ascites
Study: 4043200
Drug: Piretanide treatment
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide treatment in patients with gross ascites
Study: 27521483
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose radiation (LDR)
Study: 12574564
Drug: NXY-059 915
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 915 mg over 1 hour followed by 420 mg/h for 71 hours
Study: 12574564
Drug: NXY-059 1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 1820 mg for 1 hour followed by 844 mg/h for 71 hours
Study: 12148471
Drug: Chlormadinone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone (2 mg/day for 5 days every month)
Study: 12148471
Drug: Ethinylestradiol 35
Normalized name: Ethinylestradiol 35 microgram and norethisterone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 35 micrograms plus desogestrel 150 mg (21 days every month)
Study: 2179857
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen, administered at 3, 4, and 6 months of age.
Study: 2179857
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen.
Study: 7398002
Drug: Persantine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persantine plus aspirin (PR/A)
Study: 27568513
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone treatment
Study: 22037139
Drug: Daily tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tDCS sessions
Study: 22037139
Drug: Second daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second daily tDCS sessions
Study: 16180627
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor agonist bromocriptine
Study: 10787766
Drug: All women
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All women (treatment and control)
Study: 1289589
Drug: Cefprozil (CFPZ)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil (CFPZ) administered at a mean dose of 8.6 mg/kg in 3-4 divided doses for an average of 7 days.
Study: 1289589
Drug: Cefprozil (CFPZ)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil (CFPZ) administered at doses of 4.0, 7.5, and 15.0 mg/kg to 9 children.
Study: 31218077
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate 240 mg
Study: 15796146
Drug: Oral egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral egg albumin-based protein supplement
Study: 12188103
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with rivastigmine
Study: 10390227
Drug: Abacavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (600 mg) alone
Study: 10390227
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg) alone
Study: 10390227
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg) alone
Study: 2005227
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (5 mg daily)
Study: 26713403
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg at baseline and 6 months)
Study: 25918060
Drug: Conventional Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Medical Treatment Only (MTO)
Study: 15897671
Drug: Celecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (50 + 150 mg, cumulative dose of 200 mg)
Study: 8965118
Drug: Copolymer 1
Normalized name: glatiramer (copolymer 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer 1 (Copaxone), daily subcutaneous treatment, dosage not specified, duration not specified
Study: 6848810
Drug: Amiloride-hydrochlorothiazide combination
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride-hydrochlorothiazide combination
Study: 25918718
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia (PCA) with morphine (Group 1)
Study: 18694603
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (15 mg/Kg then 7 mg/Kg/day for one month)
Study: 18694603
Drug: Oral bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisoprolol (2.5 mg then 2.5 mg bid indefinitely)
Study: 18694603
Drug: Oral bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisoprolol
Study: 15315305
Drug: Paclitaxel (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (90 mg/m2)
Study: 15315305
Drug: Docetaxel (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (45 mg/m2)
Study: 8526970
Drug: AMPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPT plus L-dopa/carbidopa
Study: 8526970
Drug: L-dopa/carbidopa alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/carbidopa alone (placebo plus L-dopa/carbidopa)
Study: 211316
Drug: Colestyramine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestyramine (0.6 g/kg body weight)
Study: 211316
Drug: Colestipol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (0.5 g/kg body weight)
Study: 25929529
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy plus general practitioners' care
Study: 19020973
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg twice daily plus exemestane 25 mg/day
Study: 10930365
Drug: VSL#3, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3, 6 g/day for 9 months
Study: 9369848
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg vaginal progesterone every 48 hours
Study: 9369848
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg vaginal progesterone every 48 hours
Study: 1339108
Drug: Less aggressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less aggressive treatment
Study: 3909841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what was administered)
Study: 30795951
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneously every 6 months during aromatase inhibitor therapy)
Study: 30795951
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo every 6 months during aromatase inhibitor therapy)
Study: 26996580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (comprehensive rehabilitation therapy only)
Study: 21143094
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 500 (2 g daily)
Study: 21143094
Drug: Mycophenolate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate (initial dosage of 0.1 mg/kg/d)
Study: 15911155
Drug: Morphine sulfate/dextromethorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine sulfate/dextromethorphan (MS/DM) combination
Study: 8959160
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (MS)
Study: 15911155
Drug: Self-titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titrated doses of MS/DM
Study: 15911155
Drug: Self-titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titrated doses of MS
Study: 12142633
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g) during the ovulatory phase
Study: 9449270
Drug: ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg twice daily
Study: 7840070
Drug: Oat bran-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran-enriched test meal (12.8 g fiber) after 14 days of oat bran feeding (40 g/d)
Study: 7840070
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (15.6 g fiber/d)
Study: 1969060
Drug: Intravenous dithiocarb
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb zinc (DB14193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dithiocarb (DTC)
Study: 1969060
Drug: Oral dithiocarb
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb zinc (DB14193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dithiocarb (DTC)
Study: 1969060
Drug: DTC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTC (both intravenous and oral)
Study: 7433475
Drug: Oxymetazoline (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline (formulation in boric acid)
Study: 23560243
Drug: Buccal smear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal smear group (259 subjects)
Study: 16083185
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract (Kamillosan M) spray, 10 puffs of total 370 mg
Study: 16083185
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract (Kamillosan M) spray
Study: 3670972
Drug: Granulocyte transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusions of buffy coats from single units of whole blood (0.1 to 0.9 X 10(9) polymorphonuclear leukocytes per kilogram) given daily until ANC > 1,500/microL
Study: 23841567
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention including individually tailored instructions for oral and/or denture hygiene, relief of dry mouth symptoms, decrease of sugar-use frequency, use of fluoride, xylitol or antimicrobial products, and professional tooth cleaning
Study: 8866926
Drug: Hydroxychloroquine sulphate
Normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulphate 200 mg orally (three tablets)
Study: 30882150
Drug: CQ+PQ (Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ+PQ (Chloroquine + Primaquine: 0.25 mg base/kg/day for 14 days)
Study: 30882150
Drug: CQ (Chloroquine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ (Chloroquine: 25 mg base/kg given over 3 days)
Study: 27746233
Drug: Inulin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (500 mL drink containing 40 g of inulin)
Study: 27746233
Drug: Fructose (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (500 mL drink containing 40 g of fructose)
Study: 27746233
Drug: Glucose (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (500 mL drink containing 40 g of glucose)
Study: 26554558
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of aspirin once daily
Study: 15468395
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion via pain pump catheter for 48 hours
Study: 15468395
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (historical patients using oral and intravenous pain medications)
Study: 3140562
Drug: Flumazenil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1.0 mg i.v. at extubation
Study: 21205047
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) with dose adaptation based on saliva cotinine concentrations
Study: 21205047
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with nicotine patches and monthly dose decreases
Study: 16540956
Drug: ivIGMA (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivIGMA (1300 mL infused intravenously within a period of 72 hrs)
Study: 8807439
Drug: Pindolol 20
Normalized name: pindolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 20 mg b.i.d. for 4 weeks
Study: 8807439
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 10 mg b.i.d. for 4 weeks
Study: 3926732
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron therapy (mixed neutron-photon fractionated irradiation)
Study: 31560567
Drug: Waitlisted treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlisted treatment-as-usual (control) (n=18)
Study: 31852650
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of sepsis (Control)
Study: 15135009
Drug: Insulin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.05 IU/kg)
Study: 15135009
Drug: Glucose (15%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (15%, 0.5 g/kg)
Study: 9781472
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (α-tocopherol) treatment (400-1600 IU/day)
Study: 9781472
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (α-tocopherol) treatment
Study: 26598177
Drug: Preoperative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative cognitive exercise (1 hour daily for 10 days before surgery)
Study: 21784533
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg/day for six weeks